Dogwood Therapeutics filings document the regulatory record of a Delaware development-stage biopharmaceutical company focused on pain and neuropathy medicines. Its 8-K reports include financial results, Regulation FD shareholder letters, corporate updates, and material-event disclosures tied to the Halneuron® and SP16 IV development programs.
Proxy and meeting filings cover stockholder voting matters, governance, executive compensation, equity incentive plans, and Nasdaq-related approvals for warrant exercises and common stock issuances. The filing record also documents capital-structure matters, securities purchase agreements, equity awards, and risk-oriented disclosures associated with a clinical-stage biotechnology issuer.
Dogwood Therapeutics reported fourth quarter and full year 2025 results, highlighting increased investment in its pain and neuropathy pipeline and a longer cash runway. For Q4 2025, research and development expenses were $2.3 million, roughly flat year over year, while general and administrative expenses fell to $1.5 million from $5.2 million, mainly as prior transaction costs rolled off. Quarterly net loss attributable to common stockholders narrowed to $3.8 million, or $0.26 per share, from $8.2 million, or $6.29 per share.
For full year 2025, research and development expenses rose to $21.8 million from $3.5 million, driven by $12.0 million of acquired in-process R&D for SP16, higher Halneuron® Phase 2b clinical trial costs, and manufacturing and personnel spending. General and administrative expenses decreased to $6.1 million from $8.7 million, reflecting lower nonrecurring transaction and public company costs, partially offset by higher salaries, legal and professional fees, and taxes. Net loss attributable to common stockholders grew to $35.5 million, or $7.13 per share, from $12.9 million, or $12.52 per share.
As of December 31, 2025, cash and cash equivalents were $6.5 million. The company expects this balance, together with $11.4 million of net proceeds received in January 2026, to fund operations through the Halneuron® Phase 2b final data readout and into the fourth quarter of 2026. Dogwood’s pipeline centers on Halneuron®, a fast track–designated, non-opioid NaV 1.7 analgesic in Phase 2b for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist for neuropathy with a forthcoming, National Cancer Institute–funded Phase 1b CINP trial.
Dogwood Therapeutics, Inc. reported that shareholders approved the potential exercise of an unregistered common stock warrant to purchase up to 4,386,037 shares of common stock under a January 11, 2026 Securities Purchase Agreement and Nasdaq Listing Rule 5635(d).
At the Special Meeting, 29,310,309 common shares were represented, equal to 88.03% of the voting power as of the February 12, 2026 record date, establishing a quorum. The warrant exercise proposal passed with 29,286,786 votes for, 19,057 against and 4,466 abstentions. Shareholders also approved a proposal permitting adjournment of the Special Meeting if necessary, with 29,283,790 votes for, 21,571 against and 4,948 abstentions.
Grosswald Ralph reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics, Inc. reported that SVP of Operations Ralph Grosswald received a grant of stock options covering 82,500 shares of the company’s stock. These options were awarded as a form of equity compensation.
According to the disclosure, the option vests one-third on March 5, 2027, with the remaining portion vesting in equal 1/24th monthly installments thereafter, tying most of the award to continued service over time.
Dogwood Therapeutics, Inc. reported that its Chief Financial Officer, Angela Walsh, received a grant of stock options covering 82,500 shares on March 5, 2026. These options give her the right to buy company stock if and when she chooses to exercise them.
According to the filing, Walsh now holds 82,500 stock options following this award. The options vest over time, with one-third vesting on March 5, 2027 and the remaining amount vesting in equal 1/24th monthly installments thereafter, creating a multi‑year retention and incentive structure.
Dogwood Therapeutics, Inc. Chief Medical Officer Roger Michael Gendreau reported an equity compensation grant. He acquired a stock option covering 82,500 shares of Dogwood Therapeutics common stock at an exercise price of $0.00 per share.
The option was granted on March 5, 2026 and is held as a direct ownership interest. According to the disclosure, the option vests one-third on March 5, 2027, with the remaining two-thirds vesting in equal monthly installments over the following 24 months.
Duncan Gregory Scott reported acquisition or exercise transactions in this Form 4 filing.
Dogwood Therapeutics, Inc. reported that Chief Executive Officer and director Duncan Gregory Scott received a grant of stock options covering 330,000 shares on March 5, 2026. The options vest one‑third on March 5, 2027 and then in 1/24th monthly installments thereafter.
Dogwood Therapeutics, Inc. has called a virtual special stockholder meeting on March 11, 2026 to vote on two key proposals tied to a recent financing. The main item asks stockholders to approve the exercise of a Common Warrant allowing an investor to purchase up to 4,386,037 shares of common stock at an initial exercise price of $3.28 per share, issued in connection with a January 11, 2026 securities purchase agreement.
The company explains that, together with an unregistered pre-funded warrant for 2,047,089 shares, warrant-related shares represent about 20.05% of its outstanding stock immediately before that agreement, so Nasdaq Listing Rule 5635(d) requires stockholder approval before the Common Warrant can be exercised. If approved, existing holders who are not the investor would be diluted and could see reduced voting power, book value per share and future earnings per share. A second proposal would allow adjournment of the meeting to solicit more proxies if there are not enough votes to pass the warrant proposal.
Dogwood Therapeutics, Inc. has called a virtual special meeting on March 11, 2026 to ask stockholders to approve the exercise of a Common Warrant held by an investor and the related issuance of up to 4,386,037 shares of common stock, as required under a January 11, 2026 Securities Purchase Agreement and Nasdaq Listing Rule 5635(d). The company notes that the pre-funded warrant and Common Warrant issued under that agreement together represent about 20.05% of its outstanding shares immediately before the transaction, so full exercise would materially dilute existing holders’ ownership and future earnings per share. A second proposal would allow the meeting to be adjourned to solicit more proxies if there are not enough votes to approve the warrant proposal.
Dogwood Therapeutics, Inc. submitted a current report noting that it has posted a shareholder letter to its website, dated January 20, 2026. The letter provides a corporate update for shareholders and is included as Exhibit 99.1 to the report. The company specifies that this shareholder letter is being furnished for information purposes under securities regulations and is not being treated as filed or incorporated into other securities law filings.